Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Publikation

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Wissenschaftlicher Artikel/Review - 01.01.2016

Diem Stefan, Goldinger Simone M, Urner-Bloch Ursula, Siano Marco, Dummer Reinhard, Speiser Daniel E, Maillard Samia A, Rüesch Reinhard, Keller Fabienne, Flatz Lukas

Zitation

Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. J Immunother 2016; 39:379-382.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

J Immunother 2016; 39

Veröffentlichungsdatum

01.01.2016

eISSN (Online)

1537-4513

Seiten

379-382

Kurzbeschreibung/Zielsetzung

UNASSIGNED
Immunotherapy leads to significantly prolonged survival of patients with metastatic melanoma. Autoimmune side effects including colitis, dermatitis, and endocrine abnormalities are common in patients treated with ipilimumab [anti-CTLA4 (cytotoxic T-lymphocyte-associated protein 4)]. Antibodies such as pembrolizumab that interfere with the PD-1 (programmed cell death 1)/PD-L1 pathway show greater efficacy and less toxicity than ipilimumab. Here we report 2 cases of pembrolizumab-induced uveitis associated with complete or partial tumor response. We suggest that uveitis may serve as a surrogate marker for a tumor response to therapy with pembrolizumab.